Y-USA Diabetes Prevention Program
In 2011, the YMCA of the United States received a Health Care Innovation Award grant for US$11 885 134 from the CMS to expand its Diabetes Prevention Program to prediabetic Medicare recipients. Program goals were to enroll at least 10 000 people, reduce weight 5%, reduce risks of diabetes, hypertension, and hypercholesterolemia for at least half of the enrollees, and save at least US$1.8 million in Medicare costs by June 2015. 2 The program consists of 16 weekly sessions followed by 8 monthly maintenance sessions. Sessions are lead by lifestyle coaches who have at least a high school diploma plus 30 hours of training in how to lead this program in small group sessions. Sessions were provided at 17 YMCAs around the nation. The YMCAs have been providing similar programs in many more locations for several years. The focus of the Program is to improve health and to reduce medical spending by stimulating weight loss of at least 5% of body weight and increasing physical activity to 150 minutes per week.
The YMCA started enrolling people into the Program in February 13, 2013. By March 2015, 6874 had been recruited to participate in an orientation session, 5686 (82.8%) completed at least 4 sessions (including orientation), 4316 (62.9%) completed at least 9 sessions, and 1748 (25.4%) completed at least 17 sessions.
Evaluation of the Program
Research Triangle Institute was hired to evaluate the Program. The purpose of the evaluation was to measure the impact of the Program on weight, health-care utilization, and medical spending.
Design
A quasi-experimental design was used to measure utilization and medical spending, a pre-post, non-experimental design to measure the impact on weight, and pre treatment only to measure glucose.
Sample
Participants were recruited through marketing outreach by each of the participating YMCAs and referrals from local physicians. People were eligible to participate in the program if they were Medicare recipients, at least 65 years old, overweight (body mass index higher than 25), prediabetic (A1C 5.7%-6.4% or fasting glucose 110-125 mg/dL), with no previous diagnosis of diabetes, and no life-threatening conditions or mobility challenges. The comparison group for the utilization analysis was selected from nonparticipants in the CMS Chronic Conditions Warehouse and met the same criteria as participants for age, weight, existing prediabetes, and no prior diabetes diagnosis.
Measures
Enrollment was measured through YMCA administrative data for the period of January 2013 through March 2015. Healthcare utilization and spending were measured using CMS administrative and health-care claims data for the 2-year baseline period of January 2011 through December 2012 and the 2-year implementation period of January 2013 through December 2014. Note that utilization and spending data for the year of 2015 were not yet available when the analysis was conducted.
Analysis
Descriptive statistics were used to compare Medicare spending, inpatient admissions, unplanned readmission, and emergency department (ED) admissions by quarter. Regression analysis was used to illustrate Medicare spending, inpatient admissions, and ED admissions. Propensity score matching was used to select 1697 members of the comparison group to compare against 1697 members of the treatment group, with matching on total payments in the first, second, third, fourth, and fifth calendar quarters prior to enrollment, number of ED visits, and inpatient stays in calendar quarter prior to enrollment, age, sex, race, number of chronic conditions, presence of end-stage renal disease, prior diagnosis of diabetes, and having less than 1 year on Medicare.
Results
Health changes. Among those who completed at least 4 sessions, weight loss averaged 5.09 kg at 4 to 6 months and 5.31 kg at a year. Glucose was measured only prior to enrollment, so it was not possible to measure change over time.
Spending and utilization changes. Descriptive statistics showed that (1) total Medicare spending was lower in the treatment than the comparison group in 6 of the 8 quarters during the treatment period, as well as the whole treatment period, but the differences were not statistically significant because of the small sample size and high variability, (2) inpatient admissions were lower in the treatment than the comparison group in 6 of the 8 quarters during the treatment period, as well as the whole treatment period, (3) unplanned hospital admissions were lower in the treatment than the comparison group in 4 of the 8 quarters during the treatment period as well as the whole treatment period, but this finding was not very meaningful because the total number of admissions was very low, and (4) ED visits were higher in the treatment than the comparison group in 6 of the 8 quarters during the treatment period, as well as for the whole treatment period, but the total number of these visits was very low.
Regression analysis controlling for age, gender, race, disability, and end-stage renal disease showed that (1) total Medicare spending was statistically significantly lower for the treatment than the control group for the first 5 of 8 quarters during the treatment period, with lower treatment costs averaging US$455/ member/quarter or US$1780/year for the whole treatment period, (2) inpatient admissions were statistically significantly lower for the treatment than the control group for 4 of 8 quarters during the treatment period with an average of 1.1% lower admissions during the whole treatment period, and (3) there were no statistically significant differences for ED admissions.
Additional descriptive analysis showed that total Medicare spending among participants who completed at least 9 sessions was lower for 6 of the 8 treatment quarters, and the whole treatment period, compared to those who completed less than 9 sessions.
Study Limitations
The Program produced impressive results, and the study was generally well designed and executed for a community-based effectiveness study. However, the authors fully acknowledge several study limitations.
The most important limitations of the spending and utilization analysis include the more limited ability of a quasi-experimental design to control for all differences between the treatment and comparison groups, including motivation, compared to a randomized controlled design. Also, the propensity score matching reduced the sample used in the analysis from 5686 to 1697, and the extent to which the results can be extrapolated from the 1697 to the full group of 5686 is unknown. In addition, some members of the treatment group were discovered as having a previous diagnosis of diabetes, despite the requirement of no previous diagnosis to be eligible for the study. Finally, the authors did not have access to Medicare spending data for any quarters in 2015 or 2016; subsequent analysis will be required to determine whether the savings persisted for the later years and for participants who enrolled at a later date.
The biggest limitations of the analysis of health outcomes were the lack of a comparison group on weight and absence of any posttest data on glucose, the proxy measure for diabetes.
In addition to the limitations recognized by the authors, I would have liked to see analysis on the questions below:
1. How did savings compare to costs? Did the program save more than it cost? 2. How did the trend in spending before and after the Program compare for the treatment and comparison group? 3. How did physical activity change during the course of the treatment? Why was physical activity not reported? 4. How many sessions are required for impact? Does examining the impact for 1, 4, and 9 sessions tell the complete story?
Centers for Medicare and Medicaid Services Innovation Certification
This Program and evaluation were made possible by provisions Patient Protection and Affordable Care Act (ACA). Section 3021 of the ACA 3 modified section 1115A of the Social Security Act 4 to create an Innovation Center within the CMS. The purpose of the Innovation Center is to test innovation service delivery models and payment structures that reduce Medicare spending and at the same time preserve or enhance the quality of care provided to Medicare, Medicaid, and Children's Health Insurance Program beneficiaries. 5 The law authorizes the Secretary of Health and Human Services to write regulations that permit nationwide expansion of Medicare reimbursement for programs when 3 standards are met: (1) the program reduces Medicare spending without reducing the quality of care or improves the quality of care without increasing Medicare spending, (2) the CMS chief actuary certifies that expansion of the program would not increase, or would decrease, net Medicare spending, and (3) offering the program would not deny or limit coverage to recipients.
Reimbursement levels articulated by the CMS chief actuary in his March 14, 2016, memo set reimbursement levels at US$335 in the first year for participants who complete at least 9 sessions and lose 5% body weight and US$175 for people who attend at least 9 sessions but do not lose at least 5%. An additional US$25 can be reimbursed for participants who lose 9%, and an additional US$90 for people who attend 6 additional maintenance sessions in the first year and maintain the weight loss. In the second year, an additional US$180 can be reimbursed for people who maintain 5% weight loss and attend 12 maintenance sessions. In summary, a maximum of US$450 can be reimbursed for treatment programs and maintenance programs in the first year and US$180 for maintenance programs in the second year, for a total of US$630 in a 2-year period.
Next steps include (1) CMS releasing proposed regulations that clarify standards providers must meet to be eligible for reimbursement and how reimbursements will be processed, (2) a public comment period on the proposed regulations, and (3) release of the final regulations. Health advocates expect the whole process to be completed before the end of 2016.
Significance of the Program Results and CMS Innovation Certification
The Program, study and certification are significant for several reasons.
First, the success of the Program in helping enrollees lose an average of more than 5 kg of weight shows that it is feasible to stimulate weight loss in a relatively inexpensive communitybased program offered in multiple locations by staff without advanced training. Previous large-scale diabetes prevention programs that have resulted in weight loss have been offered in clinical settings with highly trained doctoral-level staff. 6 Despite the dramatic health improvements resulting from these programs, and their cost-effectiveness relative to other treatments, they have been criticized as impractical in as population-wide solution because of their high cost, averaging US$4601 per participant. 7 Second, using Medicare data on medical utilization and spending to measure the impact of a community health promotion program is innovative and opens up a new area of research on the financial impact of health promotion. Most previous studies on the financial impact of health promotion programs have used data from employer or health plan records, 8 which makes it difficult to compare results across organizations because of the differences in plan structure, pricing agreements, and other factors across health plans and employers. It is likely that using data from Medicare introduces its own complications, but at least the complications may be consistent across different studies. This analysis innovation may be the most important contribution of this study in the short term.
Third, the fact that CMS has certified that this program as one that can be ''expanded'' provides a possible source of sustainable funding for health promotion programs that can improve health and save money for people who do not have access to programs through their employers. Medicare has previously authorized funding for health promotion programs, namely the Dean Ornish Heart Disease Reversal Program. 9 That certification stimulated expansion from the intensive and expensive boutique programs offered directly by Dr Dean Ornish, to less expensive programs offered by a network of community hospitals. Those programs produced impressive health improvements, 10 but the reimbursement provided by Medicare was insufficient to sustain the programs given the inherent high cost of any service provided by a hospital. The same level of funding provided to a community organization has a much better chance of covering all the costs. If entrepreneurs can develop strategies to make programs cost-effective, this could create a medium size industry, given that an estimated 38% of all adults in the United States and 49.5% of adults 65 years or older have prediabetes. 11 With 55 million Medicare recipients in 2015, 12 this translates to a target population of 27.2 million people and potential revenues of US$17 billion (assuming US$630/person) to serve this population.
Finally, the prospect of Medicare saving US$1780/year per program participant provides a glimmer of hope that it may be possible to prevent Medicare from bankrupting the federal government in my children's lifetime. 13 It is not realistic to assume that all 27 million Medicare recipients with prediabetes can be recruited into diabetes prevention programs. Indeed, the YMCA has been successful in reaching only 6874 of the 10 000 they aspire to recruit into their program. However, if all 27.2 million were recruited and had successful outcomes, this would produce annual savings of more than US$48 billion. This is consistent with savings estimates projected by Dr Ken Thorp in 2013. 14 
Conclusion
The success of this YMCA program to reduce weight and Medicare spending in combination with CMS' decision to authorize reimbursement for this program could stimulate rapid growth of community-based efforts to prevent diabetes and eventually to prevent or reverse other chronic health conditions for Medicare recipients. If successful, these programs have potential to improve the older adults' health and reduce Medicare spending. 
